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Background: Abnormal hemograms are common manifestations and important predictive tools for morbidity in
the human immunodeficiency virus (HIV) infection. Few studies have been reported on the blood profile of HIV
antiretroviral therapy (ART) naive subjects, therefore this study aimed to quantitatively and qualitatively describe the
blood cell profile of HIV ART naive patients, and to describe the occurrence of the blood cytopenias by CD4 cell
counts and WHO clinical stage.
Methods: This cross-sectional study of ART naive HIV patients was done at the Yaounde University Teaching Hospital
(YUTH). For eligible participants, a structured questionnaire was filled and a clinical examination was done. Blood samples
were collected for the measurement of full blood count and CD4 cell count. Blood films were made for the cytological
examination of the blood samples and a reticulocyte count was done by the cresyl blue stain method.
Results: Of 81 cases reviewed, 66 (81.5%) had a blood cell disorder. The main qualitative blood disorders on the blood
film were metamyelocytes (37.1%), toxic neutrophils (33.3%), stab neutrophils (29.6%), anisocytosis (35.6%) hypochromia
(32.1%) and giant platelets (22.2%). Anaemia (62.9%) was the most common quantitative disorder of which 86.3% had
low reticulocyte counts. Participants with low CD4 counts and advanced clinical stages had a greater occurrence of blood
cytopenias (p-values <0.05).
Conclusion: In the HIV infection, peripheral blood cell abnormalities affect all cell lineages, with anaemia being the most
frequent single blood cell abnormality. Blood cytopenias mainly occur in advanced immunosuppression and clinical
stages. Although all HIV patients may have blood cell disorders, those with advanced disease are more prone to develop
them.
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The Human Immunodeficiency Virus (HIV) infection
causes the Acquired Immunodeficiency Syndrome (AIDS),
which is a systemic disorder characterized by severe defi-
ciency in cellular immune responses. Besides infectious
complications, several peripheral blood cell abnormalities
have been reported in HIV infection, of which anaemia and
neutropenia are reportedly the most common [1-4].* Correspondence: wankahpaul@gmail.com
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unless otherwise stated.Amid the multifactorial causes of anaemia and neutro-
penia, several studies agree that inadequate hematological
production due to bone marrow suppression by HIV
infection through abnormal cytokine expression, and the
alteration of the bone marrow microenvironment is pre-
ponderant [5-7]. On the other hand, thrombocytopenia is
usually caused by immune-mediated destruction of plate-
lets, in addition to inadequate production [8]. Other
causes of cytopenias in HIV infected patients include
treatment-related adverse events, opportunistic infections,
malignancies, drugs (zidovudine and cotrimoxazole) and
other pre-existing or co-existing medical problems [3,9,10].l Ltd. This is an Open Access article distributed under the terms of the Creative
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cell depletion and progression to AIDS and is one of the
strongest predictors of poor responses to antiretroviral
therapy (ART) and HIV-related mortality [1,11].
Hematological abnormalities have been documented
as strong independent predictors of morbidity and mor-
tality in HIV infected individuals [1,3,12]. Although it is
not part of the criteria for initiating therapy nor used by
the World Health Organization (WHO) for staging HIV,
peripheral blood cell abnormalities in an abnormal
hemogram are important prognostic tools for morbidity
in HIV infection and AIDS [1,3]. There are several re-
ports that anaemic HIV patients have a higher morbidity
and mortality rate than those without anaemia [13-15].
Few studies have been done in sub-Saharan Africa on
the peripheral blood cell abnormalities of HIV infected
persons, despite them being common manifestations of
HIV infection and AIDS, which may have a considerable
impact on the patient’s wellbeing, and treatment (anti-
retroviral regimens containing zidovudine would not be
used by patients having severe anaemia or pancyto-
penia). The 2001 Mbanya et al. [16] study at the Central
Hospital of Yaounde, done among ART naive AIDS pa-
tients revealed that 95.4% of AIDS patients had morpho-
logical blood cell disorders compared to 32.2% amongst
healthy controls. Thus, given that ART naive AIDS
patients have a significantly high prevalence of periph-
eral blood abnormalities, this study was carried out at
the Yaounde University Teaching Hospital (YUTH) of
Cameroon to further determine if this was alike for HIV
ART naive patients of all WHO clinical stages and im-
munological classes (CD4 counts), and also to determine
if the clinical or immunological severity of HIV would
predispose to peripheral blood cytopenias.Methods
Study setting and study population
This was a cross-sectional study of antiretroviral therapy
naive HIV-infected people who enrolled at the HIV clinic
of the Yaounde University Teaching Hospital (YUTH)
between August 2013 and February 2014. Consenting HIV
infected adults (>18 years) who were not yet on antiretro-
viral medications, were recruited consecutively into the
study. Pregnant HIV infected adults, and those on tubercu-
losis medication or cotrimoxazole prophylaxis were ex-
cluded from the study.Ethical considerations
Ethical clearance was obtained from the National Ethical
Committee, Cameroon. Permission for the conduct of the
study was obtained from the Yaounde University Teaching
Hospital. After informing study participants of the objec-
tives of the study and assuring them of confidentiality oftheir data, written informed consent was taken from all the
participants.
Data collection
Data on the socio-demographic characteristics of the par-
ticipants was collected using a pre-tested and structured
questionnaire by interview. Clinical data was collected dur-
ing a clinical examination, when symptoms and signs that
define the WHO clinical stage of HIV disease [17] were re-
corded on the questionnaire.
For the full blood count (FBC), blood smear and re-
ticulocyte count, blood was collected into a tube con-
taining Ethylene Diamine Tetra- Acetate (EDTA) at the
YUTH hematology laboratory. The FBC were performed
using the HumaCount Plus automated blood analyser
(Human GmbH, Weisbaden, Germany) less than 2 hours
after venesection. Reticulocyte count was done by stand-
ard methods [18] and the blood smear was stained by
the MayGrunwald and Giemsa method [19] and read by
a pathologist.
The participants were then referred to the Chantal
Biya International Reference Center (CIRCB) where the
CD4 count was done using the Becton Dickinson FACS-
Calibur system (Becton Dickinson, Singapore).
Administrative authorisations were obtained from the
directors of both centers for the usage of their facilities.
Statistical analysis
The occurrence of qualitative peripheral blood cell ab-
normalities were expressed as proportions or percent-
ages and were classified as categorical variables.
Reticulocyte counts were used to qualify anaemia as re-
generative or aregenerative (aregenerative anaemia with
reticulocyte counts <150,000/mm3) [18].
The Chi-square test was used to assess the presence
of statistically significant association between the quan-
titative peripheral blood cell abnormalities, anaemia
(Hemoglobin < 12 g/dl for women and < 13 g/dl for
men) [20], leucopenia (leucocyte count <4 × 109 cells/L)
[21] and thrombocytopenia (platelet count < 150 × 109
cells/L) [21], and their occurrence in the different WHO
HIV clinical stages [17] and WHO HIV immunological
classes [17]. In all cases P-value less than 0.05 was con-
sidered as statistically significant.
Statistical analyses were performed using the Epi Info
7 statistical software.
Results
General characteristics of study participants
During the study period we identified 124 ART naïve
HIV infected people, and 43 were excluded because they
were either on tuberculosis treatment, cotrimoxazole
prophylaxis or pregnant. The remaining 81 cases were
reviewed consisting of 53 (65.4%) women and 28 (34.6%)
Table 2 Full blood count results of antiretroviral naïve HIV
positive adult patients at the Yaounde University Teaching
Hospital Clinic from August 2013-February 2014
Parameter (n = 81) Mean value ± SD Range (min-max)
Total WBC x 109/L 5.1 ± 1.8 1.6-10.6
Neutrophils 2.4 ± 1.2 0.7-5.1
Monocytes 0.4 ± 0.3 0.1-1.1
Lymphocytes 1.9 ± 1.3 0.3-6.7
Total RBC x1012/L 4.4 ± 0.9 2.2-6.6
Haemoglobin (g/dl) 10.8 ± 2.5 5.1-15.8
Hematocrit (%) 33.6 ± 7.3 17.1-50.0
MCV (fl) 77.1 ± 10.1 53.0-95
MCH (pg) 25.2 ± 4.2 16.7-33.9
MCHC (g/dl) 32.0 ± 1.8 29.6-36.0
Reticulocyte x 109/L 44.5 ± 34.1 8-153
Total platelet count x109/L 256.2 ± 113.9 35.0-556.0
WBC white blood cell count, RBC red blood cell count, MCV mean corpuscular
volume, MCH mean corpuscular haemoglobin, MCHC mean corpuscular
haemoglobin concentration.
Wankah et al. BMC Hematology 2014, 14:15 Page 3 of 6
http://www.biomedcentral.com/2052-1839/14/15men. The mean age of the participants was 37.9 ±
10.8 years, range 22–70. All the participants had never
been on antiretroviral therapy (Table 1).
The majority of our research participants, 38 (46.9%),
were asymptomatic, while 26 (32.2%) had severe im-
munosuppression (Table 1).
Peripheral blood cell parameters and abnormalities
66 of the participants had at least one quantitative or
qualitative peripheral blood cell disorder, giving a preva-
lence of 81.5%.
Table 2 shows that the mean leucocyte and platelet
counts were within the normal range, while the mean
haemoglobin concentration (10.8 ± 2.1 g/dL) was lower
than normal. The mean CD4+ cell count was 298.7 ±
216.2 cells/mm3.
Anaemia was the most frequent single quantitative
hematological abnormality, occurring in 51 (62.9%) cases,
of which 44 (86.3%) were aregenerative. Leucopenia
occurred in 28 (34.6%) cases while thrombocytopenia oc-
curred in 22 (27.1%) cases.
Qualitative disorders occurred in all the peripheral
blood cell lineages, with the most frequent being theTable 1 Characteristics of antiretroviral naïve HIV positive
adult patients at the Yaounde University Teaching
Hospital Clinic from August 2013-February 2014
Variables HIV patients (n = 81)
Age
< 25 years 15 (18.6%)
25-45 years 49 (60.5%)














WHO Immunological class (CD4 cell count)
Not significant immunosuppression (>500/mm3) 16 (19.7%)
Mild immunosuppression (350-499/mm3) 19 (23.5%)
Advanced immunosuppression (200-349/mm3) 20 (24.6%)
Severe immunosuppression (<200/mm3) 26 (32.2%)presence of metamyelocytes, toxic neutrophils, anisocy-
tosis, hypochromia and giant platelets on the blood films
(Table 3).
The occurrence of the peripheral blood cytopenias in the
WHO clinical and immunological stages
Tables 4 and 5 both show that anaemia, leukopenia and
thrombocytopenia are all strongly and directly related to
CD4 cell counts and WHO disease stage, where the low-
est prevalence of blood cytopenias is among those with
clinical stage 1/CD4 cell count >500/μL, and the highest
prevalence of all three cytopenias is among those with
severe immunosuppression and stage 4 disease (p < 0.05
for all). With the exception of leucopenias by WHO dis-
ease stage, these all demonstrate graded associations.
Discussion
Peripheral blood cell abnormalities in HIV ART naive
patients are multifactorial in nature (immune mecha-
nisms, drugs, opportunistic infections or direct insult of
HIV). The 81.5% prevalence of qualitative and quantita-
tive peripheral blood cell disorder in the hemogram of
ART naïve HIV patients in this study concurs with the
findings of a similar study on AIDS patients [16]. Mba-
nya et al. [16] worked on symptomatic HIV patients who
probably had severe immune deficits, meanwhile 46.9%
of our research participants were asymptomatic, reinfor-
cing the observation that HIV causes peripheral blood
cell disorders in all infected patients indiscriminate of
clinical stage or CD4 cell count.
The prevalence of anaemia, leucopenia and thrombo-
penia in this study variably concurs and contrasts with
the findings of similar studies [4,22,23]. Possible reasons
Table 3 Frequency of occurrence of qualitative blood cell
disorders on blood film per lineage
Type of variation Number of
cases (n)
Percentage (%) 95% CI
Leucocyte lineage
Metamyelocytes 30 37.1 26.6-48.5
Toxic neutrophils 27 33.3 23.2-44.7
Stab neutrophil 24 29.6 19.9-40.8
Pelger-like neutrophil 24 29.6 19.9-40.8







Atypical lymphocytes 10 12.4 6.1-21.5
Binucleated lymphocyte 2 2.5 0.3-8.6
Erythrocyte lineage
Anisocytosis 28 35.6 24.3-45.9
Hypochromia 26 32.1 22.1-43.4
Microcytosis 22 27.2 17.9-38.2
Poikilocytosis 10 12.6 6.1-21.5
Nucleated red cells 4 4.94 1.4-12.2
Macrocytes 2 2.5 0.3-8.6
Red cell inclusion 1 1.3 0.03-6.7
Polychromasia 1 1.3 0.03-6.7
Thrombocyte lineage
Giant platelets 18 22.2 13.7-32.8
Clustered platelets 8 9.9 4.4-18.5
N total cases, n number of participants having the cytological abnormality on
the blood film.
Table 4 The occurrence of peripheral cytopenias in the




(CD4 cells/μl) [N] (n) % (n) % (n) %
No deficiency
(>500) [16]
(7) 43.8 (3) 18.8 (0) 0
Mild (350–499) [19] (9) 45.0 (5) 25.0 (4) 20
Advanced
(200–350) [20]
(13) 68.4 (6) 31.6 (4) 21
Severe (<200) [26] (22) 84.6 (14) 58.9 (14) 53.8
P-values <0.05 <0.05 <0.05
WHO World Health Organization, N number of participants per immunological
class, n number of participants per immunological class with a
given cytopenia.
Table 5 The occurrence of peripheral cytopenias in the





(n) % (n) % (n) %
Stage 1 [38] (19) 50.0 (9) 23.7 (2) 5.3
Stage 2 [19] (11) 57.9 (5) 26.3 (2) 10.5
Stage 3 [11] (8) 72.7 (7) 63.6 (8) 72.7
Stage 4 [13] (13) 100 (7) 53.8 (10) 76.9
P-values <0.05 <0.05 <0.05
WHO World Health Organization, N number of participants per immunological class,
n number of participants per immunological class with a given cytopenia.
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these different studies are the cut-off values used for an-
aemia and leucopenia, the local prevalence of parasitic
infections such as malaria or hook-worms, variations in
local nutritional patterns or the number of female partic-
ipants of the respective studies. There is also a racial dis-
parity, with Africans having lower leucocyte counts.
Although all HIV infected patients may have a periph-
eral blood cytopenia, patients with advanced disease and
low CD4 counts (Tables 4 and 5) are more likely to develop
them, as reported in several studies [8,24-26]. This is im-
portant for caregivers at the HIV clinic, because some drugs
like zidovudine and cotrimoxazole are myelotoxic and
should not be administered to patients with severe cytope-
nias, thus all HIV patients, especially those with advanced
disease, should systematically do a full blood count before
initiation of antiretroviral therapy.
Given that anaemia in ART naive HIV patients is
mostly aregenerative with reticulocyte counts less
than 150 × 109/L [3], HIV caregivers should orientateetiological investigations towards causes of inadequate
bone marrow response which may be, bone marrow sup-
pression due to the HIV virus (upregulation of cytokines in
the bone marrow), nutrient deficiency, chronic opportunis-
tic infections (tuberculosis, Mycobacterium avium complex,
cytomegalovirus) or drugs (acyclovir, cotrimoxazole). Ap-
propriate management of anaemia in HIV depends on a
good etiological diagnosis which starts by knowing if it is
peripheral or central origin.
The erythrocyte lineage abnormalities observed on the
blood films (Table 3) may result from iron deficiency
anaemia which could be due to parasitic infections or
nutritional deficiency [3]. Being in a tropical region,
parasitic infections [27] could contribute to the occurrence
of this anaemia. Macrocytosis which is often associated
with zidovudine and stavudine treatment regimens was not
a feature of these patients since our study group were naïve
for antiretroviral treatment. Furthermore folate deficiency,
vitamin B 12 deficiency, dyserythropoiesis and megalo-
blastic maturation which has been reported by several
investigators [3,16,24,25] as a cause of anaemia in HIV pa-
tients could explain the 2.5% frequency of macrocytosis in
the study. The morphological abnormalities found amongst
the leucocytes were mainly of the granulocytic lineage with
the presence of discrete numbers of young cells, but also
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neutrophils (29.6%) which indicate bacterial infections.
These findings are similar to those of Mbanya et al. [16]
who had a prevalence of 34% for pelger-like neutrophils
amongst the AIDS group, and which was significantly dif-
ferent from the control group. The major platelet abnor-
malities were giant platelets which represented 22.2% in
this study. Given that there are qualitative peripheral blood
cell disorders affecting all the cell lineages in HIV infection,
and there is no pathognomonic morphological blood cell
abnormality in HIV infection, it is important that patholo-
gists include HIV as differential diagnoses of abnormal
blood films (especially in high prevalence areas).
Because of a lack of resources, this study was limited
in that the sample size was small and it does not address
hemoglobinopathies. Also, there was no comparison
done to an HIV-uninfected group in Yaounde to show
what blood cell disorders may be driven by local factors
versus HIV-infection. Despite this, the study provides
valuable information on the peripheral blood cell profile
of antiretroviral naïve HIV patients focusing on the
quantitative and qualitative disorders as read on the
blood film by a pathologist. Reticulocyte counts which
are not systematically done in our setting were included
in this study, so as to determine if anaemia was of cen-
tral or peripheral origin. It would be interesting to study
other hematological parameters (like coagulation profile)
that may be altered in antiretroviral naïve HIV patients.
Conclusion
Several quantitative and qualitative peripheral blood cell
disorders occur in ART naïve HIV infected patients, the
most common of which is anaemia. These peripheral
blood cell disorders occur in all WHO clinical and im-
munological HIV stages and they are most common in
people with profound and advanced immune deficien-
cies. It is important that blood pathologist include HIV
as a differential diagnosis of an abnormal hemogram,
given the high prevalence cytological disorders in the
hemogram of HIV infected individuals.
We thus recommend at the end of this study that phy-
sicians should screen for hematological abnormalities in
all HIV infected patients, especially those with advanced
disease, and health regulators should provide automatic
blood counters that systematically do reticulocyte counts
in HIV clinics.
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